来自 Maksym Misichenko · Yahoo Finance ·
AI智能体对这条新闻的看法
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
风险: Regulatory tail risk and payer acceptance for one-time edits
机会: Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
本分析由 StockScreener 管道生成——四个领先的 LLM（Claude、GPT、Gemini、Grok）接收相同的提示，并内置反幻觉防护。 阅读方法论 →
Eli Lilly and Company (纽约证券交易所:LLY) 是
12 最具盈利能力的值得投资的股票之一。
2026年5月25日，Eli Lilly and Company (纽约证券交易所:LLY) 公布了 Verve-102（一种旨在通过单次输注持久性地关闭肝脏中的 PCSK9 基因并降低血清低密度脂蛋白胆固醇的实验性体内碱基编辑药物）的 Phase 1b Heart-2 研究的积极结果。在对 35 名参与者的中期分析中，Verve-102 的一种剂量产生了剂量依赖性的平均 PCSK9 降低幅度，从 0.3 mg/kg 剂量到 1.0 mg/kg 剂量，范围为 51% 到 88%。相应的平均 LDL-C 降低幅度分别为 9%、44%、45%、33%、51% 和 62%，治疗后可观察到长达 18 个月的持久性。
2026年5月21日，Wolfe Research 表示，Eli Lilly and Company (纽约证券交易所:LLY) 报告了 retatrutide 的关键 Phase 3 结果，显示出“领先的”体重减轻幅度，在 80 周时可高达 26.1%，在 104 周时可超过 30%，在 BMI 较高的参与者中。Wolfe 表示，数据还显示出关键的心脏代谢风险标志物得到广泛改善，进一步巩固了 Eli Lilly 在 GLP-1 领域的领导地位和肥胖治疗领域的优势。Wolfe 维持对该公司股票的“跑赢大盘”评级和 1,350 美元的股价目标。
与此同时，RBC Capital 维持对 Eli Lilly and Company (纽约证券交易所:LLY) 的“跑赢大盘”评级和 1,250 美元的股价目标。RBC 表示，retatrutide Phase 3 试验是一场干净的胜利，理由是安全记录良好，并且在所有剂量下都具有最佳效果。RBC 表示，它预计 retatrutide 将于 2027 年上市，2030 年的销售额为 49 亿美元，2034 年的销售额为 110 亿美元，成功概率为 70%。
Eli Lilly and Company (纽约证券交易所:LLY) 国际上发现、开发、生产和销售人类药物产品。
虽然我们承认 LLY 作为一项投资的潜力，但我们认为某些 AI 股票具有更大的潜在回报，并且风险更低。如果您正在寻找一个极具低估值的 AI 股票，并且有望从特朗普时代的关税和回流趋势中获益，请参阅我们关于最佳短期 AI 股票的免费报告。
阅读下一篇：33 支在 3 年内可能翻倍的股票 和 Cathie Wood 2026 年投资组合：10 支值得购买的最佳股票。** **
披露：无。 在 Google News 上关注 Insider Monkey。
四大领先AI模型讨论这篇文章
"Early-stage gene-editing data and retatrutide results are encouraging but remain too preliminary to override pipeline and competitive risks."
The article spotlights early positive data for Verve-102 (51-88% PCSK9 reduction, up to 62% LDL-C drop) and retatrutide Phase 3 weight loss up to 26.1%, plus analyst targets of $1,250-$1,350. These support LLY's cardiometabolic pipeline strength, yet the piece is framed within a promotional push for unrelated AI stocks, and dates reference 2026 events. Phase 1b results involve only 35 participants with variable durability, while retatrutide modeling assumes 70% success and 2027 launch. Missing context includes base-editing safety risks, obesity market competition, and how in vivo gene editing scales commercially versus existing GLP-1 therapies.
The strongest case against a neutral stance is that dose-dependent, durable LDL-C reductions in humans could de-risk the platform faster than expected, justifying premium multiples if retatrutide hits modeled $11B sales by 2034.
"Verve-102's PCSK9 knockdown doesn't proportionally reduce LDL-C, raising questions about mechanism and real-world efficacy before Phase 2 data; retatrutide upside is real but already priced in at current multiples."
Verve-102's Phase 1b data is genuinely impressive on the surface—88% PCSK9 reduction at top dose, 18-month durability—but the LDL-C response is oddly flat: only 62% reduction despite 88% target suppression. This disconnect suggests either target engagement doesn't linearly drive efficacy, or there's compensatory biology we don't yet understand. The retatrutide Phase 3 wins are real, but RBC's $11B 2034 sales forecast assumes zero competition erosion in a crowded GLP-1 market by then. More critically: both programs are years from peak revenue, and LLY's current valuation already prices in obesity dominance. The article's pivot to 'AI stocks offer greater upside' is editorial noise, but it flags real opportunity cost.
If Verve-102's PCSK9 suppression translates to durable cardiovascular outcomes in Phase 2b/3, a one-time genetic edit could disrupt the entire statin and PCSK9 inhibitor market—potentially $50B+ TAM—making current LLY valuation cheap on a 10-year view.
"Lilly is transitioning from a traditional pharmaceutical company to a platform-based biotech powerhouse capable of dominating both the obesity market and the next generation of genetic cardiovascular medicine."
Eli Lilly is effectively building a 'cardiometabolic fortress.' The Verve-102 data, while early-stage, represents a paradigm shift from chronic GLP-1 injections to potentially one-and-done genetic medicine, which would fundamentally disrupt the long-term revenue model for chronic care. When combined with the 26-30% weight loss efficacy of retatrutide, Lilly is positioning itself to capture both the lifestyle and the underlying genetic drivers of cardiovascular disease. However, the market is currently pricing in perfection. With a forward P/E ratio exceeding 60x, any regulatory hiccup in the 2027 retatrutide launch or unforeseen long-term safety signals from gene editing will lead to a violent de-rating of the stock.
The immense cost and clinical complexity of in vivo gene editing may limit Verve-102 to a niche, ultra-high-risk patient population, failing to achieve the mass-market scale required to justify Lilly's current premium valuation.
"Verve-102’s early data are not a reliable foundation for near-term upside given unresolved safety/regulatory risks and lack of clinical outcome proof."
Verve-102 Phase 1b data show intriguing, but very early signals: N=35, dose-responsive PCSK9 reductions (51–88%) and LDL-C drops up to ~62% with durability claimed to 18 months. Yet safety data are absent, delivery/remedy specifics unclear, and in vivo base editing carries significant off-target and immune risk, plus an uncertain regulatory path for a permanent liver edit. Translation from LDL-C reduction to reduced ASCVD events is not demonstrated. The obesity program (retatrutide) also remains early-stage; even with strong signals, long-run safety, cost, and payer dynamics will drive real upside. The stock’s rally could be fragile if these risks materialize or if timelines slip.
The strongest counter: Phase 1b size and scope are too small to infer durable clinical benefit; safety/off-target risks and a murky regulatory path could derail Verve-102 before Phase 2/3 even starts, making upside speculative.
"Verve-102's manufacturing and reimbursement hurdles are understated relative to retatrutide's scalable peptide production."
Gemini assumes Verve-102 scales like retatrutide into a broad cardiometabolic fortress, yet in vivo base editing demands specialized GMP manufacturing of LNPs with lot-to-lot editing consistency that Lilly has never demonstrated at obesity-drug volumes. This bottleneck, plus one-time therapy reimbursement fights with payers, could confine Verve-102 to narrow high-risk segments even if durability holds, capping revenue well below the $50B TAM cited elsewhere and amplifying de-rating risk if timelines slip.
"Manufacturing scale is achievable; the real gate is whether payers value one-time durability over chronic therapy economics."
Grok's manufacturing bottleneck argument is sharp, but it conflates two separate problems. LNP consistency is solvable—Moderna and BioNTech scaled it to billions of doses. The real constraint is payer reimbursement for one-time edits in a $100K+ range competing against $300/month GLP-1s. That's a willingness-to-pay problem, not a GMP problem. If Verve-102 shows durable CV outcomes, payers may accept it; if not, manufacturing capacity becomes irrelevant.
"The permanent nature of in vivo base editing creates a regulatory and safety barrier that prevents it from scaling like transient mRNA therapies."
Claude, your LNP manufacturing comparison is dangerous. Moderna's mRNA degrades; it doesn't permanently alter the genome. The regulatory and safety burden of delivering a CRISPR-based base editor—which carries permanent off-target risk—is orders of magnitude higher than a transient vaccine. Scaling this isn't just a volume issue; it's a massive clinical trial hurdle. If the FDA requires long-term monitoring for oncogenic risk, the 'one-and-done' cost-benefit analysis against GLP-1s collapses entirely, regardless of payer willingness.
"Long-term safety tail risk and payer/regulatory hurdles for permanent genome edits could cap Verve-102's upside even if CV outcomes look durable."
Gemini's one-and-done thesis hinges on favorable CV outcomes and payer acceptance, but permanent liver base editing carries a long-tail safety burden regulators will scrutinize for decades. Even with durable LDL-C/ASCVD signals, long-term oncogenic and off-target risks could trigger post-approval surveillance costs, denial of coverage, and slower uptake than implied. Manufacturing isn't the only bottleneck—the regulatory tail risk and payer risk could erode the multiple from a 50B TAM to a fraction of that.
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Regulatory tail risk and payer acceptance for one-time edits